D'ANDRA LINDBUCHLER: Open Payments
NPI 1740664028 · MOOSIC, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$967 in 58 payments from 10 companies in 2025. Trend: 2023 $592 · 2024 $704 · 2025 $967
Food & beverage: $967
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 11 | $255 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $195 |
| ABBVIE INC. | 16 | $176 |
| Alkermes, Inc. | 6 | $111 |
| Neurocrine BioSciences, Inc. | 4 | $69 |
| Vanda Pharmaceuticals Inc. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: COBENFY, CAPLYTA, VRAYLAR, ARISTADA, INGREZZA, FANAPT, UZEDY, LYBALVI.
Industry payments across PA — which companies pay providers there.
